Pembrolizumab: given beside what is tested

1,547 studies: usual care or a partner of the new treatment. Page 12 of 16. Open to participants first (520), then studies with results posted, then the rest; newest registration first within each.

Overcoming Primary Resistance to Immunotherapy in Metastatic MelanomaCompletedNCT05304546Phase 2 Report a problem
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and MelanomaCompletedNCT05303493Phase 1 Report a problem
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)CompletedNCT05298423Phase 3 Report a problem
Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck CancerActive, not recruitingNCT05286060Phase 2 Report a problem
ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid TumorsCompletedNCT05277402Phase 1 Report a problem
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT05271604Phase 2 Report a problem
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.Active, not recruitingNCT05271318Phase 1/2 Report a problem
Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLCStatus unknownNCT05267366Phase 2 Report a problem
ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without MetastasesTerminatedNCT05265013Phase 2 Report a problem
Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid TumoursTerminatedNCT05255484Phase 1/2 Report a problem
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)Active, not recruitingNCT05239728Phase 3 Report a problem
A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid TumorsWithdrawnNCT05234606Phase 1/2 Report a problem
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBCWithdrawnNCT05233696Phase 2 Report a problem
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or FailureStatus unknownNCT05233358Not applicable Report a problem
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCCWithdrawnNCT05220748Phase 1 Report a problem
Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsTerminatedNCT05220722Phase 1/2 Report a problem
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingNCT05217446Phase 2 Report a problem
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsActive, not recruitingNCT05215574Phase 1 Report a problem
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT05215340Phase 3 Report a problem
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) AdenocarcinomaTerminatedNCT05207722Phase 1/2 Report a problem
Clinical Trial of GAIA-102 for Advanced and Relapse NSCLCTerminatedNCT05207371Phase 1/2 Report a problem
T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsActive, not recruitingNCT05200559Phase 1/2 Report a problem
Personalized DC Vaccines in Non Small Cell Lung CancerActive, not recruitingNCT05195619Phase 1 Report a problem
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1 Report a problem
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)Active, not recruitingNCT05186974Phase 2 Report a problem
A Phase 1/2 Study of BA3071 in Patients With Solid TumorsActive, not recruitingNCT05180799Phase 1/2 Report a problem
A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid TumorsCompletedNCT05176509Phase 1 Report a problem
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma PatientsActive, not recruitingNCT05176470Phase 1 Report a problem
Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC PatientsStatus unknownNCT05174832Phase 2 Report a problem
JAB-BX102 Monotherapy and Combination With Pembrolizumab in Adult Patients With Advanced Solid TumorsCompletedNCT05174585Phase 1/2 Report a problem
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT05172258Phase 2 Report a problem
Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung CancerWithdrawnNCT05171062Phase 1 Report a problem
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma PatientsStatus unknownNCT05170256Phase 2 Report a problem
Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)CompletedNCT05165433Phase 1 Report a problem
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast CancerTerminatedNCT05163223Phase 2 Report a problem
Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)CompletedNCT05159778Phase 2 Report a problem
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)Active, not recruitingNCT05155254Phase 3 Report a problem
Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsActive, not recruitingNCT05145907Phase 2 Report a problem
A Study of NDI 1150-101 in Patients With Solid TumorsActive, not recruitingNCT05128487Phase 1/2 Report a problem
RBN-2397 in Combination With Pembrolizumab in Patients With SCCLActive, not recruitingNCT05127590Phase 1/2 Report a problem
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid TumorsActive, not recruitingNCT05117476Phase 1 Report a problem
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung CancerTerminatedNCT05117242Phase 2 Report a problem
A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsCompletedNCT05108623Phase 1 Report a problem
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage AdenocarcinomaSuspendedNCT05101356Phase 1/2 Report a problem
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT05096663Phase 2/3 Report a problem
SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast CancerWithdrawnNCT05093387Phase 1 Report a problem
A Beta-only IL-2 ImmunoTherapY StudyActive, not recruitingNCT05086692Phase 1/2 Report a problem
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid TumorsTerminatedNCT05083481Phase 1 Report a problem
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid TumorsCompletedNCT05082610Phase 1 Report a problem
ASTEROID: A Trial of ASTX660 in Combination With PembrolizumabActive, not recruitingNCT05082259Phase 1 Report a problem
Brazilian Lung Immunotherapy StudyCompletedNCT05081674Phase 2 Report a problem
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT05081609Phase 1/2 Report a problem
Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With PembrolizumabStatus unknownNCT05075122Phase 2 Report a problem
FT538 in Combination With Monoclonal Antibodies in Advanced Solid TumorsTerminatedNCT05069935Phase 1 Report a problem
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung CancerTerminatedNCT05062980Phase 1 Report a problem
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsActive, not recruitingNCT05060432Phase 1/2 Report a problem
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid TumorsCompletedNCT05054348Phase 1 Report a problem
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformeActive, not recruitingNCT05053880Phase 1/2 Report a problem
PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaActive, not recruitingNCT05034536Phase 2 Report a problem
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)Active, not recruitingNCT05030506Phase 1 Report a problem
Gut Microbiota Reconstruction for NSCLC ImmunotherapyStatus unknownNCT05008861Phase 1 Report a problem
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in AdultsTerminatedNCT04999202Phase 1 Report a problem
FRAME-001 Personalized Vaccine in NSCLCStatus unknownNCT04998474Phase 2 Report a problem
Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable MelanomaWithdrawnNCT04995094Phase 2 Report a problem
Nous-PEV: a Novel Immunotherapy for Lung Cancer and MelanomaTerminatedNCT04990479Phase 1 Report a problem
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer PatientsWithdrawnNCT04987996Phase 2 Report a problem
Olinvacimab With Pembrolizumab in Patients With mTNBCTerminatedNCT04986852Phase 2 Report a problem
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)Active, not recruitingNCT04976634Phase 2 Report a problem
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced MelanomaActive, not recruitingNCT04971499Phase 1/2 Report a problem
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerActive, not recruitingNCT04958239Phase 1 Report a problem
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)Active, not recruitingNCT04956640Phase 1/2 Report a problem
Fecal Microbial Transplantation Non-Small Cell Lung Cancer and MelanomaActive, not recruitingNCT04951583Phase 2 Report a problem
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingNCT04938817Phase 1/2 Report a problem
GEN1046 Safety and PK in Subjects With Advanced Solid MalignanciesCompletedNCT04937153Phase 1 Report a problem
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingNCT04930783Phase 1 Report a problem
Microbiota Transplant in Advanced Lung Cancer Treated With ImmunotherapyCompletedNCT04924374Not applicable Report a problem
ALPN-202 With PD-1 Inhibition in Advanced MalignanciesTerminatedNCT04920383Phase 1 Report a problem
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT04913337Phase 1/2 Report a problem
A Randomized, Placebo Controlled Study to Evaluate the Safety and Potential Efficacy of MS-20 in Combination with Pembrolizumab for the Treatment of Non-Small-Cell Lung CancerCompletedNCT04909034Not applicable Report a problem
A Study of Pembrolizumab and Radiation Therapy in People With MesotheliomaActive, not recruitingNCT04897022Phase 1 Report a problem
EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT04892472Phase 2 Report a problem
The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)SuspendedNCT04866810Not applicable Report a problem
A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 AntibodyStatus unknownNCT04866485Phase 1 Report a problem
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell CancerTerminatedNCT04862455Phase 2 Report a problem
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid TumorsStatus unknownNCT04859777Phase 1 Report a problem
A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of ChemoimmunotherapyTerminatedNCT04856176Phase 2 Report a problem
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaActive, not recruitingNCT04848519Phase 2 Report a problem
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerCompletedNCT04847466Phase 2 Report a problem
Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsCompletedNCT04840394Phase 1 Report a problem
Electroporation Potentiated Immunotherapy in CancerActive, not recruitingNCT04835402Phase 2 Report a problem
A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanomaTerminatedNCT04834973Phase 1/2 Report a problem
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell CancerWithdrawnNCT04834349Phase 2 Report a problem
A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and NeckCompletedNCT04830592Phase 1 Report a problem
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedNCT04830124Phase 2 Report a problem
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT04815720Phase 1/2 Report a problem
Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCCCompletedNCT04811027Phase 2 Report a problem
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT04799054Phase 1/2 Report a problem
Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)CompletedNCT04793815Not applicable Report a problem
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver CancerTerminatedNCT04777708Early Phase 1 Report a problem
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Active, not recruitingNCT04736706Phase 3 Report a problem

← Pembrolizumab